Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
Adam, aggressive, aim, allogeneic, annum, appeal, axicabtagene, billion, biosimilar, Blueprint, borrowing, BPCIA, ceiling, ciloleucel, CMS, Coast, Congressional, coupled, CRS, curative, cytokine, delisted, deregulation, diagnosed, die, differentiated, diffuse, disabled, District, domestic, easier, Eighty, encourage, entertain, entirety, EU, fall, fatal, feedback, follicular, forefront, formulary, FSS, fueled, furniture, genetically, Gilead, graft, Guard, guideline, GvHD, hindsight, hospital, HSCT, identification, implicit, incentivize, increasingly, inflation, inflationary, inherited, injectable, inNote, Inspector, Kymriah, laid, lived, Logal, lymphocytic, lymphoplasmacytic, mantle, military, modality, mortality, nearest, needy, neurologic, NHL, notification, Onthe, outbreak, outpatient, overallotment, passed, penny, pharmacy, pocket, prefunded, presidential, pro, proportionately, rata, refractory, Reg, regained, release, repay, residual, retroactive, ROU, soldpursuant, soliciting, SRC, Statute, sublicensee, substitution, syndrome, takeover, TCR, tech, tender, tisagenlecleucel, Treasurer, TRICARE, unclear, unconstitutional, unfolding, Vice, wecompleted, XBIOW, Yescarta, zone
Removed:
acting, Adult, affirmative, aforementioned, allocable, Altered, amend, American, amortization, anniversary, anthracycline, antineoplastic, April, assumption, assured, attempted, biomarker, breast, buyer, calculate, calling, carboplatin, catch, center, characterize, chemotherapeutic, cisplatin, cohort, collectability, compound, copy, cumulative, cytotoxic, Dana, depot, determinable, discharge, dispose, divided, dose, Downstream, doxorubicin, elucidate, Emergent, ER, estrogen, expiry, explanatory, exploratory, exposure, Farber, fifty, greatest, Harvard, Hematology, hemoglobin, ifosfamide, immunomodulatory, insensitive, judged, kinase, knowledge, leased, Ledgemont, Maguire, match, MD, Medicine, minimize, NE, negligible, organizational, pathway, percent, persuasive, PJSC, possession, presently, Professor, promissory, provisional, PulmoXen, ranking, receivable, reconciling, reorganization, restating, restructure, rh, Richard, Room, round, scheduled, School, Scott, Signaling, Simplifying, Society, staffing, standing, Stone, successor, suggest, surviving, Taxol, TEAE, TNBC, topotecan, travel, underwritten, unsolicited, Virexxa, Washington
Filing tables
Filing exhibits
- 10-K Annual report
- 4.1 Description of Registrants Securities Registered
- 10.50 Letter Agreement
- 10.51 Form of Letter Agreement
- 10.52 Stock Option Grant Notice
- 10.53 Stock Option Grant Notice
- 21.1 Subsidiaries of Registrant
- 23.1 Independent Registered Public Accounting Firm S Consent
- 31.1 Certification of Principal Executive Officer
- 31.2 Certification of Principal Financial Officer
- 32.1 Certification
- Download Excel data file
- View Excel data file
XBIO similar filings
Filing view
External links
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report on Form 10-K of Xenetic Biosciences, Inc. (the “Company”) for the fiscal year ended December 31, 2019, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, the undersigned officers of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:
1. | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and |
2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Dated: March 26, 2020
/s/ Jeffrey F. Eisenberg | /s/James Parslow |
Jeffrey F. Eisenberg | James Parslow |
Chief Executive Officer (Principal Executive Officer) | Chief Financial Officer (Principal Financial Officer) |